NAD(P)H Quinone Oxidoreductase 1 Inhibits the Proteasomal Degradation of the Tumour Suppressor P33(ING1b)
Overview
Affiliations
The tumour suppressor p33(ING1b) ((ING1b) for inhibitor of growth family, member 1b) is important in cellular stress responses, including cell-cycle arrest, apoptosis, chromatin remodelling and DNA repair; however, its degradation pathway is still unknown. Recently, we showed that genotoxic stress induces p33(ING1b) phosphorylation at Ser 126, and abolishment of Ser 126 phosphorylation markedly shortened its half-life. Therefore, we suggest that Ser 126 phosphorylation modulates the interaction of p33(ING1b) with its degradation machinery, stabilizing this protein. Combining the use of inhibitors of the main degradation pathways in the nucleus (proteasome and calpains), partial isolation of the proteasome complex, and in vitro interaction and degradation assays, we set out to determine the degradation mechanism of p33(ING1b). We found that p33(ING1b) is degraded in the 20S proteasome and that NAD(P)H quinone oxidoreductase 1 (NQO1), an oxidoreductase previously shown to modulate the degradation of p53 in the 20S proteasome, inhibits the degradation of p33(ING1b). Furthermore, ultraviolet irradiation induces p33(ING1b) phosphorylation at Ser 126, which, in turn, facilitates its interaction with NQO1.
Alves F, Lane D, Nguyen T, Bush A, Ayton S Signal Transduct Target Ther. 2025; 10(1):2.
PMID: 39746918 PMC: 11696223. DOI: 10.1038/s41392-024-02088-5.
Impact of NQO1 dysregulation in CNS disorders.
Yuhan L, Khaleghi Ghadiri M, Gorji A J Transl Med. 2024; 22(1):4.
PMID: 38167027 PMC: 10762857. DOI: 10.1186/s12967-023-04802-3.
Riboflavin compounds show NAD(P)H dependent quinone oxidoreductase-like quinone reducing activity.
Nagase M, Sakamoto M, Amekura S, Akiba S, Kashiba M, Yokoyama K J Clin Biochem Nutr. 2023; 73(1):52-60.
PMID: 37534093 PMC: 10390810. DOI: 10.3164/jcbn.22-140.
Tu H, Zhang Z, Li J, Shi S, Costa M Am J Cancer Res. 2023; 13(6):2307-2322.
PMID: 37424815 PMC: 10326586.
NQO1 regulates cell cycle progression at the G2/M phase.
Oh E, Kim H, Kim C, Lee J, Kim C, Lee J Theranostics. 2023; 13(3):873-895.
PMID: 36793872 PMC: 9925316. DOI: 10.7150/thno.77444.